⭐ALL Hub spotlight | ECOG-ACRIN E1910: A phase III trial⭐ . The ECOG ACRIN-led E1910 trial is investigating the efficacy and safety of blinatumomab + chemotherapy vs chemotherapy alone in patients with newly diagnosed BCR::ABL1-negative B-ALL; see the latest results here.

New data 📝 An analysis presented by Anna Candoni at #EHA2025 shows 80% of patients with Ph– B-ALL treated with blinatumomab following 1L pediatric-inspired chemotherapy achieved MRD negativity. Learn more: #ALLsm #leusm #MedNews #MedEd

⭐ALL Hub spotlight: Inotuzumab ozogamicin dose optimization in adults with B-ALL ⭐ During ASH 2024, Daniel DeAngelo reported that the higher starting dose of 1.8 mg/m2/cycle of InO provides a favorable balance of efficacy and safety in adult patients with R/R B-ALL.

DeAngelo presented data at the 66th ASH Annual Meeting and Exposition supporting the FDA-approved higher starting dose of 1.8 mg/m2/cycle of InO, vs the lower dose of 1.2 mg/m2/cycle, in balancing safety and efficacy in adults with R/R B-ALL. #ALL #MedEd

📝 Data presented by Elias Jabbour at #EHA2025 demonstrate 12-month OS estimates of 63% and 70% with 250 μg/500 μg and 500 μg/1,000 μg subcutaneous blinatumomab in patients with R/R B-ALL. More news: #ALLsm #leusm #MedNews #MedEd

New data📝 Phase I/II trial results, presented by Elias Jabbour at #EHA2025, show CR/CRh rates of 75% and 79% with 250 μg/500 μg and 500 μg/1,000 μg subcutaneous blinatumomab, respectively, in patients with R/R B-ALL. Learn more: #ALLsm #leusm #MedEd

📝A pooled analysis, presented by Elias Jabbour at #EHA2025, shows more patients with R/R B-ALL treated with ≤3.3 mg/m2 inotuzumab ozogamicin proceeded to HSCT compared with >3.3 mg/m2 (74% vs 46%). More news: #ALLsm #leusm #MedNews #MedEd

New data 📝 A pooled analysis of three studies, presented by Elias Jabbour at #EHA2025, demonstrated improved PFS and OS outcomes with ≤3.3 mg/m2 vs >3.3 mg/m2 inotuzumab ozogamicin in patients with R/R B-ALL. Learn more: #ALLsm #leusm #MedNews #MedEd

📝 Initial results from a phase II trial presented at #ASCO25 found that early MRD negativity was improved with tafasitamab plus DA-EPOCH ± R in ND Ph− B-ALL. Rates of MRD negativity by C1 and C4 were 40% and 71%. More news: . #ALLsm #leusm #MedEd

New data 📝 Preliminary results from the phase I/II SYRUS trial, presented by Ibrahim Aldoss at #EHA2025, show surovatamig (AZD0486) was well tolerated, with Grade 3 CRS occurring in 6% of patients with R/R B-ALL. Learn more: #ALLsm #leusm

New data📝Initial results from a phase II trial presented by Kopmar at #ASCO25 show that adding tafasitamab to DA-EPOCH ± R improved early MRD-negativity in adults with newly diagnosed Ph− B-ALL, with manageable toxicity. Learn more: #ALLsm #leusm #MedEd

🚨 News 🚨.Obecabtagene autoleucel has been granted marketing authorization by the @EU_Commission for the treatment of patients aged ≥26 years with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Read more: #ALLsm #leusm #MedNews #MedEd

Did you know you can filter content on the ALL Hub website depending on your specific interests – whether that is by ALL type, therapeutics, trials, or congresses? . 👉 . #allsm #leusm #MedEd

📝 Preliminary results from the phase I/II SYRUS trial, presented by Ibrahim Aldoss at #EHA2025, found that surovatamig (AZD0486) achieved an ORR of 83% at a target dose of 15 mg in patients with R/R B-ALL. More news: . #ALLsm #leusm #MedicalCongress

🚨 News 🚨. @EU_Commission has granted marketing authorization to obecabtagene autoleucel for the treatment of patients aged ≥26 years with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Read more: #ALLsm #leusm #MedNews #MedEd

📝 Follow-up results from ZUMA-3 presented at #EHA2025 demonstrate a 5-year OS rate of 40% with a median OS of 25.6 months with brexu-cel for adult patients with R/R B-ALL. More news: . #ALLsm #leusm #MedNews #MedEd

New data 📝 5-year follow-up results from ZUMA-3 presented at #EHA2025 show brexu-cel continues to provide durable benefit for adults with R/R B-ALL regardless of age, prior therapy, or subsequent allo-HSCT status. Learn more: #ALLsm #leusm #MedNews

📝 A subgroup analysis from the ECOG-ACRIN E1910 trial presented at #EHA2025 supports the use of Blina + chemo consolidation in patients aged <55 y with MRD-negative BCR::ABL1-negative BCP-ALL. More news: . #ALLsm #leusm #MedNews #MedEd

New data 📝 Subgroup analysis from ECOG-ACRIN E1910 presented at #EHA2025 shows higher 3-year OS and RFS with Blina + chemo (92% & 86%) vs chemo (67% & 66%) in patients <55 y with MRD-negative BCR::ABL1-negative B-ALL. Learn more: #ALLsm #leusm #MedNews

📝 Long-term follow-up data from the CALGB 10403 study presented by Wendy Stock at #EHA2025 found that MRD negative vs positive status was associated with longer OS in AYA patients with ALL (p = 0.0037). More news: . #ALLsm #leusm #MedicalCongress #MedEd

New data 📝 Long-term follow-up data from the CALGB 10403 study presented by Wendy Stock at #EHA2025 show a median survival of 142 months, with 56% of AYA patients with ALL achieving 10-year survival. Learn more: #ALLsm #leusm #MedicalCongress #MedEd